World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: IRCT
Last refreshed on: 22 February 2018
Main ID:  IRCT2013040812758N2
Date of registration: 2013-05-01
Prospective Registration: No
Primary sponsor: Iraqi Board for Medical Specializations
Public title: Treatment of acne vulgaris
Scientific title: Topical Adapalene 0.1% Gel versus Topical Combination of (Tretinoin 0.025% and Erythromycin 4%) Gel in Treatment of AcneVulgaris
Date of first enrolment: 2009-10-01
Target sample size: 36
Recruitment status: Complete
URL:  http://en.irct.ir/trial/12757
Study type:  interventional
Study design:  Randomization: N/A, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.  
Phase:  N/A
Countries of recruitment
Iraq
Contacts
Name: Dr.Ammar Faisal Hameed   
Address:  Medical city61106 Baghdad Iraq
Telephone: 00
Email: amar@uobaghdad.edu.iq
Affiliation:  Department of Dermatology-Baghdad University
Name: Dr.Husam Ali Salman   
Address:  Medical collection office, P.O. Box 61211 12114 baghdad Iraq
Telephone: 00
Email: husjob2000@yahoo.com
Affiliation:  Department of Dermatology-Baghdad medical college
Key inclusion & exclusion criteria
Inclusion criteria: Inclusion criteria: All patients with mild to moderate acne vulgaris will enrolled in the study. All patients must without any systemic and / or topical treatment for at least 2 months before starting the study.
Exclusion criteria: Patients excluded from the study were those with severe acne, nodulocystic acne, patients with systemic diseases, pregnant and lactating women.

Exclusion criteria:

Age minimum: no limit
Age maximum: no limit
Gender: Both
Health Condition(s) or Problem(s) studied
Acne vulgaris
Acne vulgaris.
Acne vulgaris
Intervention(s)
A split face method for application of treatment will used in which each patient instructed to use a combined gel formula of tretinoin 0.025% and erythromycin 4% on the right side of the face and adapalene 0.1% gel on the left side..
A split face method for application of treatment will used in which each patient instructed to use a combined gel formula of tretinoin 0.025% and erythromycin 4% on the right side of the face and adapalene 0.1% gel on the left side.
Treatment - Drugs
Primary Outcome(s)
Change in acne scoring.(mild,moderate,severe)Mild acne in which the count of pustules is less than 20 and the count of papules is less than 10. Timepoint: Each patient was instructed to use the same amount of both gels (finger tip method), ½ hour in the 1st night then wash and increase the time by ½ hour in the successive nights till reach 8 hours; thereafter to keep the applications till morning. The duration of therapy was 6 weeks and follow up for another 6weeks. Method of measurement: The clinical evaluation was done every 3 weeks by 2 dermatologists; the assessment was carried out by counting the inflammatory lesions (papules and pustules) and watching any local side effects.
Secondary Outcome(s)
The satisfaction of the patient with the treatment. Timepoint: The clinical evaluation was done every 3 weeks. Method of measurement: The satisfaction of the patients to the treatment is classified into:1- Full satisfaction.2- Partial satisfaction.3 - No satisfaction.
Secondary ID(s)
Source(s) of Monetary Support
Iraqi Board for Medical Specializations
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date:
Contact:
Iraqi Board for Medical specializations
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history